<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00761319</url>
  </required_header>
  <id_info>
    <org_study_id>C-08-047</org_study_id>
    <nct_id>NCT00761319</nct_id>
  </id_info>
  <brief_title>Phase III Clinical Trial of TRAVATAN Z in Ocular Surface Health</brief_title>
  <official_title>An Evaluation of the Ocular Surface Health in Subjects Using TRAVATAN Z® Ophthalmic Solution Versus XALATAN® Ophthalmic Solution</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alcon Research</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alcon Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to compare two ophthalmic solutions in patients with open-angle
      glaucoma or ocular hypertension.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Change at Day 90 From Baseline (Day 0) in Ocular Surface Disease Index (OSDI) Score</measure>
    <time_frame>Day 0, Day 90</time_frame>
    <description>The OSDI is a 12-question validated questionnaire (resultant overall 0-100 score) used to measure ocular symptoms, visual function, and environmental factors that may affect a patient's vision, where 0 = normal and 100 = severe. The OSDI questionnaire was administered at both visits and completed by the patient with no assistance from the office staff, physician, or anyone else. A negative number represents a perceived improvement in ocular health.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients With Corneal Fluorescein Staining Score = 0</measure>
    <time_frame>Day 90</time_frame>
    <description>The corneal surface was assessed by the investigator and graded on a scale of 0-3, where 0 = Absent (no staining present) and 3 = Severe (&gt;50% coverage). Percentage of patients with score = 0 at 90 days was calculated by dividing the number of patients with score = 0 by tht total number of patients analyzed.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">705</enrollment>
  <condition>Open-angle Glaucoma</condition>
  <condition>Ocular Hypertension</condition>
  <arm_group>
    <arm_group_label>Travoprost</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One drop self-administered in the study eye(s) once daily for 90 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Latanoprost</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One drop self-administered in the study eye(s) once daily for 90 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®)</intervention_name>
    <description>Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop a day, dosed topically for 90 days. Referred to as travoprost.</description>
    <arm_group_label>Travoprost</arm_group_label>
    <other_name>TRAVATAN Z®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Latanoprost ophthalmic solution 0.005% (XALATAN®)</intervention_name>
    <description>Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop a day, dosed topically for 90 days. Referred to as latanoprost.</description>
    <arm_group_label>Latanoprost</arm_group_label>
    <other_name>XALATAN®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years or older.

          -  Ocular Surface Disease Index (OSDI) score and corneal fluorescein staining score as
             specified in protocol.

          -  Diagnosis of open-angle glaucoma or ocular hypertension in at least one eye.

          -  Intraocular pressure (IOP) controlled with latanoprost 0.005% (XALATAN®) for at least
             one continuous month prior to Visit 1.

          -  Willing and able to discontinue use of any topical ocular medicine other than the
             study medication for the duration of the study, including artificial tears.

          -  Best corrected visual acuity of -0.6 logMAR or better in each eye.

          -  Other protocol-defined inclusion criteria may apply.

        Exclusion Criteria:

          -  Any medical condition (systemic or ophthalmic) that may preclude safe administration
             of the test article.

          -  Use of contact lenses within 30 days of Visit 1.

          -  Use of contact lenses during the study.

          -  Participation in an investigational drug or device study within 30 days of entering
             this study.

          -  Other protocol-defined exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 25, 2008</study_first_submitted>
  <study_first_submitted_qc>September 25, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 29, 2008</study_first_posted>
  <results_first_submitted>March 30, 2012</results_first_submitted>
  <results_first_submitted_qc>March 30, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 23, 2012</results_first_posted>
  <last_update_submitted>April 20, 2012</last_update_submitted>
  <last_update_submitted_qc>April 20, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 26, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Open-angle glaucoma</keyword>
  <keyword>ocular hypertension</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Latanoprost</mesh_term>
    <mesh_term>Travoprost</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were recruited from 78 US study centers. Eligible patients having a diagnosis of open-angle glaucoma or ocular hypertension and on XALATAN® monotherapy for at least one month immediately prior to Visit 1 were enrolled.</recruitment_details>
      <pre_assignment_details>705 patients were enrolled in this study. 701 patients were evaluated for safety. Baseline characteristics are presented for all patients who received test article and had at least one on-therapy visit (intent to treat): 652.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Travoprost</title>
          <description>One drop self-administered in the study eye(s) once daily for 90 days</description>
        </group>
        <group group_id="P2">
          <title>Latanoprost</title>
          <description>One drop self-administered in the study eye(s) once daily for 90 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="353"/>
                <participants group_id="P2" count="352"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="305"/>
                <participants group_id="P2" count="318"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="48"/>
                <participants group_id="P2" count="34"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Noncompliance</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Nonspecified</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Missing</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Travoprost</title>
          <description>One drop self-administered in the study eye(s) once daily for 90 days</description>
        </group>
        <group group_id="B2">
          <title>Latanoprost</title>
          <description>One drop self-administered in the study eye(s) once daily for 90 days</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="318"/>
            <count group_id="B2" value="334"/>
            <count group_id="B3" value="652"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66.3" spread="11.8"/>
                    <measurement group_id="B2" value="66.3" spread="10.9"/>
                    <measurement group_id="B3" value="66.3" spread="11.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <description>One gender response is missing from the Travatan Z arm.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="185"/>
                    <measurement group_id="B2" value="216"/>
                    <measurement group_id="B3" value="401"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="132"/>
                    <measurement group_id="B2" value="118"/>
                    <measurement group_id="B3" value="250"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Change at Day 90 From Baseline (Day 0) in Ocular Surface Disease Index (OSDI) Score</title>
        <description>The OSDI is a 12-question validated questionnaire (resultant overall 0-100 score) used to measure ocular symptoms, visual function, and environmental factors that may affect a patient's vision, where 0 = normal and 100 = severe. The OSDI questionnaire was administered at both visits and completed by the patient with no assistance from the office staff, physician, or anyone else. A negative number represents a perceived improvement in ocular health.</description>
        <time_frame>Day 0, Day 90</time_frame>
        <population>Intent to treat. All patients who received test article and had at least one on-therapy study visit were evaluable for the intent-to-treat analysis. Last-observation-carried-forward was used to impute values for dropouts and for missing data on a scheduled study visit during the masked treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>Travoprost</title>
            <description>One drop self-administered in the study eye(s) once daily for 90 days</description>
          </group>
          <group group_id="O2">
            <title>Latanoprost</title>
            <description>One drop self-administered in the study eye(s) once daily for 90 days</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change at Day 90 From Baseline (Day 0) in Ocular Surface Disease Index (OSDI) Score</title>
          <description>The OSDI is a 12-question validated questionnaire (resultant overall 0-100 score) used to measure ocular symptoms, visual function, and environmental factors that may affect a patient's vision, where 0 = normal and 100 = severe. The OSDI questionnaire was administered at both visits and completed by the patient with no assistance from the office staff, physician, or anyone else. A negative number represents a perceived improvement in ocular health.</description>
          <population>Intent to treat. All patients who received test article and had at least one on-therapy study visit were evaluable for the intent-to-treat analysis. Last-observation-carried-forward was used to impute values for dropouts and for missing data on a scheduled study visit during the masked treatment period.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="305"/>
                <count group_id="O2" value="314"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.1" spread="1.0"/>
                    <measurement group_id="O2" value="-10.2" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients With Corneal Fluorescein Staining Score = 0</title>
        <description>The corneal surface was assessed by the investigator and graded on a scale of 0-3, where 0 = Absent (no staining present) and 3 = Severe (&gt;50% coverage). Percentage of patients with score = 0 at 90 days was calculated by dividing the number of patients with score = 0 by tht total number of patients analyzed.</description>
        <time_frame>Day 90</time_frame>
        <population>Intent to treat. All patients who received test article and had at least one on-therapy study visit were evaluable for the intent-to-treat analysis. Last-observation-carried-forward was used to impute values for dropouts and for missing data on a scheduled study visit during the masked treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>Travoprost</title>
            <description>One drop self-administered in the study eye(s) once daily for 90 days</description>
          </group>
          <group group_id="O2">
            <title>Latanoprost</title>
            <description>One drop self-administered in the study eye(s) once daily for 90 days</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients With Corneal Fluorescein Staining Score = 0</title>
          <description>The corneal surface was assessed by the investigator and graded on a scale of 0-3, where 0 = Absent (no staining present) and 3 = Severe (&gt;50% coverage). Percentage of patients with score = 0 at 90 days was calculated by dividing the number of patients with score = 0 by tht total number of patients analyzed.</description>
          <population>Intent to treat. All patients who received test article and had at least one on-therapy study visit were evaluable for the intent-to-treat analysis. Last-observation-carried-forward was used to impute values for dropouts and for missing data on a scheduled study visit during the masked treatment period.</population>
          <units>Percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="306"/>
                <count group_id="O2" value="318"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.6"/>
                    <measurement group_id="O2" value="38.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected for the duration of the study: 22 October 2008 to 15 September 2009.</time_frame>
      <desc>This reporting group includes all patients who received the test article. Two patients experienced more than one adverse event.</desc>
      <group_list>
        <group group_id="E1">
          <title>Travoprost</title>
          <description>One drop self-administered in the study eye(s) once daily for 90 days</description>
        </group>
        <group group_id="E2">
          <title>Latanoprost</title>
          <description>One drop self-administered in the study eye(s) once daily for 90 days</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (11.0)</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="353"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="348"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="348"/>
              </event>
              <event>
                <sub_title>Myocardial Infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="348"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="348"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Adverse drug reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="348"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="348"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="348"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="348"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="348"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="348"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Mastectomy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="348"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombophlebitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="348"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="348"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="348"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Alcon reserves the right of prior review of any publication or presentation of information related to the study.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The subjective nature of the OSDI may not be sensitive enough to detect the effects of preservatives on the corneal surface. The measurement and quantification of OSD remains a considerable clinical challenge. (Pflugfelder and Baudoin, 2011)</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Director of Alcon Clinical</name_or_title>
      <organization>Alcon Research, Ltd.</organization>
      <phone>1-888-451-3937</phone>
      <email>medinfo@alconlabs.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

